Corcept Therapeutics (NASDAQ:CORT) Insider Joseph Douglas Lyon Sells 5,000 Shares of Stock

Corcept Therapeutics Incorporated (NASDAQ:CORT) insider Joseph Douglas Lyon sold 5,000 shares of Corcept Therapeutics stock in a transaction dated Wednesday, May 27th. The stock was sold at an average price of $65.00, for a total value of $325,000.00. Following the transaction, the insider directly owned 6,230 shares in the company, valued at approximately $404,950. The trade was a 44.52% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

Corcept Therapeutics Stock Up 1.6%

Corcept Therapeutics stock traded up $1.11 during midday trading on Friday, hitting $69.49. The company’s stock had a trading volume of 774,694 shares, compared to its average volume of 1,782,915. Corcept Therapeutics Incorporated has a 12 month low of $28.66 and a 12 month high of $91.00. The company has a market capitalization of $7.46 billion, a PE ratio of 198.55 and a beta of 0.36. The stock’s 50-day moving average price is $47.30 and its 200-day moving average price is $52.18.

Corcept Therapeutics (NASDAQ:CORT) last announced its quarterly earnings data on Thursday, April 30th. The biotechnology company reported ($0.30) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.11) by ($0.19). Corcept Therapeutics had a return on equity of 7.40% and a net margin of 6.14%.The business had revenue of $164.90 million during the quarter, compared to analyst estimates of $185.83 million. During the same period in the prior year, the firm earned $0.17 EPS. The business’s revenue for the quarter was up 4.9% on a year-over-year basis. As a group, equities analysts anticipate that Corcept Therapeutics Incorporated will post 0.52 EPS for the current year.

Analyst Upgrades and Downgrades

CORT has been the subject of several recent research reports. Canaccord Genuity Group increased their target price on shares of Corcept Therapeutics from $110.00 to $135.00 and gave the company a “buy” rating in a research note on Thursday. Truist Financial raised shares of Corcept Therapeutics to a “strong-buy” rating in a research note on Wednesday, March 25th. Zacks Research upgraded Corcept Therapeutics from a “strong sell” rating to a “hold” rating in a report on Monday, May 4th. Piper Sandler lifted their target price on Corcept Therapeutics from $73.00 to $88.00 and gave the stock an “overweight” rating in a report on Friday, May 1st. Finally, UBS Group set a $135.00 target price on Corcept Therapeutics in a report on Thursday. One equities research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating and three have assigned a Hold rating to the company. According to MarketBeat.com, Corcept Therapeutics presently has an average rating of “Moderate Buy” and an average price target of $88.83.

Hedge Funds Weigh In On Corcept Therapeutics

A number of hedge funds have recently modified their holdings of the stock. First Trust Advisors LP grew its position in Corcept Therapeutics by 213.5% during the 1st quarter. First Trust Advisors LP now owns 2,173,376 shares of the biotechnology company’s stock worth $87,609,000 after purchasing an additional 1,480,059 shares in the last quarter. AQR Capital Management LLC lifted its holdings in shares of Corcept Therapeutics by 546.9% in the third quarter. AQR Capital Management LLC now owns 1,507,209 shares of the biotechnology company’s stock valued at $125,264,000 after purchasing an additional 1,274,215 shares in the last quarter. Geode Capital Management LLC boosted its position in shares of Corcept Therapeutics by 38.0% in the fourth quarter. Geode Capital Management LLC now owns 2,668,918 shares of the biotechnology company’s stock worth $92,892,000 after buying an additional 734,646 shares during the period. Norges Bank purchased a new position in shares of Corcept Therapeutics during the fourth quarter valued at $24,213,000. Finally, JPMorgan Chase & Co. grew its holdings in shares of Corcept Therapeutics by 223.4% during the third quarter. JPMorgan Chase & Co. now owns 849,864 shares of the biotechnology company’s stock valued at $70,632,000 after buying an additional 587,053 shares in the last quarter. 93.61% of the stock is currently owned by institutional investors and hedge funds.

Key Headlines Impacting Corcept Therapeutics

Here are the key news stories impacting Corcept Therapeutics this week:

• Positive Sentiment: Canaccord Genuity raised its price target on Corcept Therapeutics to $135 from $110 and reiterated a buy rating, signaling greater confidence in upside potential. Canaccord Genuity price target update
• Positive Sentiment: HC Wainwright lifted its 2026 earnings estimates for CORT, including higher Q3, Q4, and full-year EPS forecasts, while maintaining a buy rating and $95 target. Higher profit expectations often support the stock. HC Wainwright estimate revisions
• Positive Sentiment: Corcept said it plans to resubmit the NDA for relacorilant in Cushing’s syndrome, which keeps a key pipeline asset alive and appears to be the main business-specific catalyst behind the recent rally. Relacorilant NDA resubmission article
• Neutral Sentiment: Stockholders approved an expanded incentive plan and board-related matters at the 2026 annual meeting; this is supportive of governance but not a major immediate earnings driver. Stockholders approve expanded incentive plan and board

About Corcept Therapeutics

Corcept Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing drugs that modulate the effects of cortisol, a hormone implicated in a range of severe metabolic, oncologic and psychiatric disorders. The company’s scientific platform centers on selectively targeting the glucocorticoid receptor to counteract the harmful consequences of excess cortisol, a strategy designed to address diseases with significant unmet medical needs.

The company’s flagship marketed product, Korlym (mifepristone), is approved in the United States for the treatment of hyperglycemia secondary to Cushing’s syndrome in patients who have type 2 diabetes or glucose intolerance and are not candidates for surgery.